Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.25)
# 2,589
Out of 5,157 analysts
53
Total ratings
32%
Success rate
3.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $4.86 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $10.69 | +68.38% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $2.38 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.37 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $79.63 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $40.25 | +148.45% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $5.00 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.62 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.39 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $18.44 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.08 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.39 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $86.92 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.21 | +55.76% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $3.36 | +286.90% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $21.86 | -63.40% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.86
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $10.69
Upside: +68.38%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.38
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $79.63
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $40.25
Upside: +148.45%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.00
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.62
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.39
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.44
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.08
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.39
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $86.92
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.21
Upside: +55.76%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $3.36
Upside: +286.90%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $21.86
Upside: -63.40%